Member Exclusive

Novel class of proteasome inhibitor may provide benefit in cancer treatment

Researchers at the California Institute of Technology (Pasadena, CA, USA) have suggested that a new class of proteasome inhibitor that targets the 19S subunit may be beneficial in overcoming cancer cell resistance to traditional proteasome inhibitors.

Go to the profile of Rachel Coleby
Mar 10, 2017

Please sign in or register for FREE

Register to RxNet

RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.